The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
Abstract
BACKGROUND: In patients experiencing motor fluctuations, a major treatment challenge is the reduction of "off" time, particularly upon awakening. Rotigotine (Neupro) is a novel dopaminergic agonist with 24-hour transdermal delivery. METHODS: A randomized, double-blind, placebo-controlled trial (PREFER Study) was performed to assess efficacy and safety with two targeted transdermal doses of rotigotine in subjects with advanced Parkinson disease with > or =2.5 hours of daily "off" time. Subjects were randomized to receive placebo patches (n = 120) or rotigotine up to either 8 mg/24 hours (n = 120) or 12 mg/24 hours (n = 111). The primary efficacy measures compared changes from baseline to the end of week 24 in the number of daily hours "off" and responder rates for subjects achieving > or =30% reduction in "off" time. RESULTS: Compared to placebo, there were significant decreases in mean "off" time of 1.8 hours/day for the rotigotine 8 mg/24 hours group and 1.2 hours/day for the 12 mg/24 hours group. For rotigotine 8 and 12 mg/24 hours groups, > or =30% responder rates were 56.6% and 55.1% compared to the 34.5% placebo response. "On" time without dyskinesia after awakening was more than doubled in both rotigotine treatment groups vs placebo. Drug-related adverse effects included typical dopaminergic side effects, which were generally mild/moderate in intensity. Patch application site reactions including erythema and pruritus were mild to moderate and transient in the majority of instances. CONCLUSIONS: Transdermal rotigotine significantly improved "off" time in subjects with Parkinson disease not optimally controlled with levodopa and was safe and well tolerated, with typical dopaminergic side effects and occasional application site reactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hauser, R. A., Friedlander, J., Zesiewicz, T. A., Adler, C. H., Seeberger, L. C., O'Brien, C. F., Molho, E. S., & Factor, S. A. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200003000-00003 · Cited by 300
Lieberman, A., Ranhosky, A., & Korts, D. (1997) · Neurology · doi:10.1212/wnl.49.1.162 · Cited by 268
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
Lieberman, A., Olanow, C. W., Sethi, K., Swanson, P., Waters, C. H., Fahn, S., Hurtig, H., Yahr, M., & the Ropinirole Study Group* (1998) · Neurology · doi:10.1212/wnl.51.4.1057 · Cited by 223
Guttman, M., & International Pramipexole-Bromocriptine Study Group (1997) · Neurology · doi:10.1212/wnl.49.4.1060 · Cited by 209
A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease
(2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1721 · Cited by 203
Newman-Tancredi, A., Cussac, D., Audinot, V., Nicolas, J.-P., De Ceuninck, F., Boutin, J.-A., & Millan, M. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039875 · Cited by 179
Pinter, M. M., Pogarell, O. M., & Oertel, W. H. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.4.436 · Cited by 155
TREATMENT OF PARKINSONISM WITH BROMOCRIPTINE
Calne, D. B., Leigh, P. N., Teychenne, P. F., Bamji, A., & Greenacre, J. K. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92219-3 · Cited by 138
Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease
Metman, L. V., Gillespie, M., Farmer, C. M., Bibbiani, F., Konitsiotis, S., Morris, M. J., Shill, H. A., Bara‐Jimenez, W., Mouradian, M. M., & Chase, T. N. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200105000-00008 · Cited by 100
Thobois, S., Vingerhoets, F. J. G., Fraix, V., Xie‐Brustolin, J., Mollion, H., Costes, N., Mertens, P., Benabid, A., Pollak, P., & Broussolle, E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.11.1705 · Cited by 83
Cited by
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
Poewe, W. H., Rascol, O., Quinn, N., Tolosa, E., Oertel, W. H., Martignoni, E., Rupp, M., & Boroojerdi, B. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70108-4 · Cited by 398
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Metadata
- Authors
- LeWitt, P. A., Lyons, K. E., & Pahwa, R.
- Venue
- Neurology
- Published
- 2007-04-17
- Volume
- 68
- Issue
- 16
- Pages
- 1262-1267
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2120044435
- Cited by
- 261
- References
- 11
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. https://app.cochat.ai/papers/10.1212/01.wnl.0000259516.61938.bb
- The paper
- LeWitt, P. A., Lyons, K. E., & Pahwa, R. (2007). Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. https://doi.org/10.1212/01.wnl.0000259516.61938.bb
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.